In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

Pheochromocytoma

British Columbia Cancer Agency – Pheochromocytoma Molecular Insight Pharmaceuticals, Inc. – Pheochromocytoma Children’s Hospital of Philadelphia – Pheochromocytoma Jubilant DraxImage Inc. – Pheochromocytoma Children’s Hospital Medical Center, Cincinnati – Pheochromocytoma University of California, San Francisco – Pheochromocytoma

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma Metanephrines in Obstructive Sleep Apnoea Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma Pheochromocytoma and Hemodynamic Instability Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection – Systematic Review and Meta-analysis Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study Blood Sampling for Neurochemical and Genetic Testing Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Dosimetry Guided PRRT With 177Lu-DOTATATE in Children Expanded Access Protocol Using 131I-MIBG Dovitinib in Neuroendocrine Tumors Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET) Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Multicenter Pheochromocytoma and Paraganglioma Evaluation A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Preoperative Alpha Blockade for Pheochromocytoma Phenoxybenzamine Versus Doxazosin in PCC Patients Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Diagnosis and Treatment of Pheochromocytoma the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma Surgeon-Anesthesiologist Collaboration Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma 131MIBG to Treat Malignant Pheochromocytoma Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma Diagnosis of Pheochromocytoma Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma